Compare Gilead Sciences, Inc. (GILD) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Invesco NASDAQ 100 ETF — how do they compare? Gilead Sciences, Inc. trades at $135.99 (market cap $168.35B), while Invesco NASDAQ 100 ETF trades at $297.75. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Invesco NASDAQ 100 ETF pays none, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | QQQM | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $307.23 |
52-Week Low | $110.56 | $229.87 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
QQQM, tracking the Nasdaq-100, trades at $298.55, up 0.59% with a bullish technical signal from moving averages. The ETF benefits from lower fees compared to QQQ, attracting cost-conscious investors. Recent news highlights its inclusion in retirement portfolios and strong inflows into Nasdaq-focused ETFs, supported by tech sector performance.
Outlook remains positive due to tech-led growth, but risks include market volatility and concentration in mega-cap stocks. The ETF offers exposure to high-growth companies, with institutional activity showing mixed signals, such as Bank of America reducing its position in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
